You are wrong. BTW, my previous post is not responding to yours. More facts are that FDA offered two options. Further animal testing is the first choice. Prana chooses to spend more than one year to work on option two. They should justify why they don't follow FDA's instruction to do/report relevant animal tests. If option two failed, will they focus on option one, or give up "commercialization in US"?
Investigating the activity spectrum for ring-substituted 8-hydroxyquinolines., page-34
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $38.48K | 12.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 77190096 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 6269051 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |